- In a clear signal to Pfizer (PFE -1.5%) that it needs to dig quite a bit deeper into its pockets, AstraZeneca (AZN -0.7%) publishes an update to its growth strategy. It states that the company's transformation to growth is underway citing its new management team plus its growing and accelerating late-stage pipeline.
- It provides long-term revenue targets for its five key growth platforms: Brilinta: $3.5B by 2023; Diabetes: $8B by 2023; Respiratory: $8B by 2023; Emerging markets: mid-to-high single digit growth; Japan: low single-digit growth.
- New revenue targets: 2017 revenues in line with 2013's and $45B by 2023.
AstraZeneca updates its value-building strategy to shareholders
From other sites
at CNBC.com (Apr 10, 2015)
at Zacks.com (Apr 8, 2015)
at Zacks.com (Apr 7, 2015)
at Investopedia (Apr 7, 2015)
at MarketRealist.com (Mar 27, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs